Grants and Contributions:
Title:
Validation Studies on Immune Modulating Therapeutic Antibodies
Agreement Number:
912341
Agreement Value:
$195,560.00
Agreement Date:
Sep 1, 2018 - Jan 31, 2020
Description:
Novelogics Biotechnology Inc. is developing an innovative antibody immunotherapy treatment for use in cancer patients that functions to restore a key component of the immune system, and which is expected to be less toxic than many traditional cancer drugs while improving patient outcomes when used with other therapies.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Port Coquitlam, British Columbia, CA V3C 6E8
Reference Number:
172-2018-2019-Q2-912341
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
824347843
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 62 days. The total amended value is 10,000 dollars.
Amendment Date
Nov 18, 2019
Recipient's Legal Name:
Novelogics Biotechnology Inc.
Federal Riding Name:
Coquitlam--Port Coquitlam
Federal Riding Number:
59008
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: